- Home
- THAR vs SILO Comparison
THAR vs SILO Comparison
Compare THAR & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- SILO
- Stock Information
- Founded
- THAR 2017
- SILO 2010
- Country
- THAR United States
- SILO United States
- Employees
- THAR N/A
- SILO N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- THAR Health Care
- SILO Consumer Discretionary
- Exchange
- THAR Nasdaq
- SILO Nasdaq
- Market Cap
- THAR 5.5M
- SILO 4.5M
- IPO Year
- THAR 2022
- SILO N/A
- Fundamental
- Price
- THAR $1.35
- SILO $0.71
- Analyst Decision
- THAR Strong Buy
- SILO
- Analyst Count
- THAR 1
- SILO 0
- Target Price
- THAR $17.00
- SILO N/A
- AVG Volume (30 Days)
- THAR 119.3K
- SILO 547.0K
- Earning Date
- THAR 08-14-2025
- SILO 08-13-2025
- Dividend Yield
- THAR N/A
- SILO N/A
- EPS Growth
- THAR N/A
- SILO N/A
- EPS
- THAR N/A
- SILO N/A
- Revenue
- THAR N/A
- SILO $72,102.00
- Revenue This Year
- THAR N/A
- SILO $1.86
- Revenue Next Year
- THAR N/A
- SILO N/A
- P/E Ratio
- THAR N/A
- SILO N/A
- Revenue Growth
- THAR N/A
- SILO N/A
- 52 Week Low
- THAR $0.95
- SILO $0.41
- 52 Week High
- THAR $6.39
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- THAR 46.35
- SILO 54.77
- Support Level
- THAR $1.15
- SILO $0.56
- Resistance Level
- THAR $1.66
- SILO $0.72
- Average True Range (ATR)
- THAR 0.12
- SILO 0.07
- MACD
- THAR 0.01
- SILO 0.00
- Stochastic Oscillator
- THAR 39.22
- SILO 65.50
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.